Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide...Read more
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug...Read more
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM)...Read more
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH...Read more
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced today that it has submitted a...Read more
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Madrigal Pharmaceuticals | 46.61 8.56 | $591.02 |
| Regeneron Pharmaceuticals | 19.25 2.57 | $767.96 |
| Eli Lilly | 14.56 1.38 | $1,071.44 |
| Mettler-Toledo | 13.09 0.94 | $1,402.51 |
| Intuitive | 10.58 1.88 | $572.47 |
| United Therapeutics | 10.13 2.00 | $517.13 |
| McKesson | 9.69 1.20 | $820.25 |
| BioMarin Pharmaceutical | 9.20 17.71 | $61.15 |
| Vertex Pharmaceuticals | 8.82 1.97 | $456.20 |
| Insmed | 8.29 4.98 | $174.84 |
| Medpace | 8.15 1.45 | $568.36 |
| argenx | 7.94 0.94 | $854.99 |
| Mirum Pharmaceuticals | 7.46 10.61 | $77.74 |
| Krystal Biotech | 7.43 3.18 | $240.80 |
| Natera | 7.22 3.21 | $231.96 |
| TransMedics | 6.64 5.48 | $127.71 |
| HCA Healthcare | 6.42 1.38 | $472.98 |
| iRhythm Technologies | 5.69 3.38 | $174.17 |
| Company | Volume | Last Trade |
|---|---|---|
| Amicus Therapeutics | 986,075,919 | $14.20 |
| ProPhase Labs | 882,779,272 | $0.13 |
| GeoVax Labs | 241,201,952 | $0.16 |
| Psyence Biomedical | 142,239,580 | $1.00 |
| IN8bio | 120,065,588 | $1.21 |
| Incannex Healthcare | 96,163,689 | $0.44 |
| Recursion | 70,183,479 | $4.31 |
| Pfizer | 58,452,347 | $25.26 |
| Altimmune | 54,601,935 | $3.89 |
| ImmunityBio | 45,159,577 | $2.08 |
| Cue Biopharma | 42,610,219 | $0.27 |
| VYNE Therapeutics | 36,245,376 | $0.57 |
| WORK Medical Technology | 35,061,727 | $0.05 |
| Merck | 34,023,177 | $101.09 |
| Iovance Biotherapeutics | 30,150,506 | $2.48 |
| NovaBay Pharmaceuticals | 30,148,737 | $5.30 |
| Zynex | 28,843,046 | $0.31 |
| Bristol-Myers Squibb | 27,951,538 | $54.19 |
| PacBio | 23,948,777 | $1.84 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
